Transferrin R
Transferrin R Informations sur la molécule
| Nom anglais | Transferrin receptor protein 1 | Nombre de médicaments commercialisés | 1 |
| Nombre de médicaments cliniques | 15 | Alias de la cible | TFRC，T9，sTfR，Transferrin receptor protein 1，TR，Transferrin Receptor，P90，Transferrin Receptor (P90， CD71)，CD71 Antigen，IMD46，CD71，TfR1，Trfr，TfR |
| Phase de R&D la plus avancée | Approved | ||
| Nom anglais | Transferrin receptor protein 1 |
| Alias de la cible | TFRC，T9，sTfR，Transferrin receptor protein 1，TR，Transferrin Receptor，P90，Transferrin Receptor (P90， CD71)，CD71 Antigen，IMD46，CD71，TfR1，Trfr，TfR |
| Nombre de médicaments commercialisés | 1 |
| Nombre de médicaments cliniques | 15 |
| Phase de R&D la plus avancée | Approved |
Transferrin R Liste de produits
- Attribut
Protein (16)Cell (1)
- Bibliothèque de produits
En ligne (17)
- Espèces
Human (7)Cynomolgus (4)Mouse (4)Rat (2)
- Étiquette
His Tag (7)His Tag & Avi Tag (4)Fc Tag (3)Tag Free (2)Fc Tag & Avi Tag (1)
- Marqueur
Unconjugated (8)Biotin-labeled (8)- (1)
Ajouter au panier
Quantité totale17
- 1
- 2
Transferrin RContexte de la molécule
CD antigen CD71 is also known as Transferrin receptor protein 1, TfR, sTfR, p90, TfR1, Trfr, which belongs to the peptidase M28 family and M28B subfamily. CD71 /TFR contains one PA (protease associated) domain. CD71 / TfR1 is required for iron delivery from transferrin to cells. CD71 is a potential new target in cases of human leukomia & lymphoma. CD71 /TFRC / TfR has been shown to interact with GABARAP and HFE.
Transferrin RAlias de la molécule
CD71,TFRC,TFR,sTfR,TfR1,Trfr,T9,p90
Informations sur les médicaments cliniques
| Nom anglais | Code de recherche | Phase de R&D | Entreprise | Indication | Essai clinique |
|---|---|---|---|---|---|
| Human apotransferrin (Sanquin Blood Supply Foundation) | Phase 3 Clinical | Sanquin Plasma Products Bv | beta-Thalassemia; Iron Metabolism Disorders | Details | |
| Delpacibart braxlosiran | AOC1020 | Phase 3 Clinical | Avidity Biosciences Inc | Foot-and-Mouth Disease; Muscular Dystrophies; Muscular Dystrophy, Facioscapulohumeral | Details |
| Delpacibart eteddesiran | AOC-1001; AOC 1001 | Phase 3 Clinical | Avidity Biosciences Inc | Genetic Diseases, Inborn; Heredodegenerative Disorders, Nervous System; Muscular Atrophy; Muscular Diseases; Muscular Disorders, Atrophic; Muscular Dystrophies; Musculoskeletal Diseases; Myotonia; Myotonic Disorders; Myotonic Dystrophy; Nervous System Diseases; Neurodegenerative Diseases; Neuromuscular Diseases | Details |
| Trontinemab | RO-7126209; RG-6102 | Phase 3 Clinical | F. Hoffmann-La Roche Ltd | Alzheimer Disease | Details |
| CX-2029 | ABBV-2029; ABBV-CX-2029; CX-2029 | Phase 2 Clinical | Abbvie Inc, Cytomx Therapeutics Inc | Carcinoma, Non-Small-Cell Lung; Esophageal Neoplasms; Head and Neck Neoplasms; Lymphoma, Large B-Cell, Diffuse; Solid tumours | Details |
| Zeleciment rostudirsen | DYNE251 | Phase 2 Clinical | Dyne Therapeutics Inc | Muscular Dystrophy, Duchenne | Details |
| AOC-1044 | AOC-1044; AOC 1044 | Phase 2 Clinical | Avidity Biosciences Inc | Muscular Dystrophy, Duchenne | Details |
| JR-446 | JR-446 | Phase 2 Clinical | Jcr Pharmaceuticals Co Ltd, Medipal Holdings Corp | Mucopolysaccharidosis III | Details |
| JR-441 | JR-441 | Phase 2 Clinical | Jcr Pharmaceuticals Co Ltd | Mucopolysaccharidosis III | Details |
| Lepunafusp alfa | JR-171 | Phase 2 Clinical | Jcr Pharmaceuticals Co Ltd | Mucopolysaccharidosis I | Details |
| PPMX-T003 | PPMX-T003 | Phase 2 Clinical | Perseus Proteomics Inc | Leukemia; Polycythemia Vera | Details |
| INA-03 | INA03 | Phase 1 Clinical | Inatherys | Leukemia; Leukemia, Myeloid, Acute; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details |
| PRX012-TfR | PRX012-TfR | Phase 1 Clinical | Prothena | Alzheimer Disease | Details |
| KK-2260 | KK2260; KK-2260 | Phase 1 Clinical | Kyowa Kirin Co Ltd | Esophageal Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck | Details |
| ABX-1100 | ABX-1100 | Phase 1 Clinical | Aro Biotherapeutics Co | Glycogen Storage Disease Type II | Details |
Informations sur les médicaments commercialisés
| Nom anglais | Code de recherche | Phase de R&D | Entreprise | Plus ancien nom de marque | Pays d'approbation le plus ancien | Indication la plus ancienne | Société d'approbation la plus ancienne | Date d'approbation la plus ancienne | Indication | Essai clinique |
|---|---|---|---|---|---|---|---|---|---|---|
| Pabinafusp alfa | JR-141 | Approved | Jcr Pharmaceuticals Co Ltd | Japan | Mucopolysaccharidosis II | Jcr Pharmaceuticals Co Ltd | 2021-03-23 | Mucopolysaccharidosis II | Details |
Avis sur les produits
***a2026-05-29
0Mettre un likeWas purchased for use in BLI, both for immobilization onto human fc binding sensors and as analyte with a biotin-labeled TfR-targeting nanobody on streptavidin. Retested for use after 1.5 years storage at -80 and still had full functional activity.- S*** 2025-11-18 0Mettre un likeUsed this material as a captured ligand in routine SPR testing on a Biacore. Material is clean, consistent, and easy to work with, and can be used to generate quality data
- ZZ2022-10-11 0Mettre un likeWe needed this product for our antibody research. ACRO managed to get it to us much faster than we expected, which made our research work very accurate. cd71 is a potential new target in human leukemia and lymphoma cases. cd71 /TFRC / TfR has been shown to interact with GABARAP and HFE. I am very pleased with the product and the quick technical support.
Charger plus
- Informations sur la molécule
- Liste de produits
- Informations sur les médicaments commercialisés
- Avis sur les produits
- Informations sur les médicaments cliniques